Tuberous sclerosis complex (TSC) is a genetic disorder that causes noncancerous tumors to grow in the brain, skin, kidneys, heart, lungs, and other organs. It affects roughly 1 in 6,000 to 1 in 18,000 live births, though the true number is likely higher because milder cases often go undiagnosed. The condition varies enormously from person to person: some people have barely noticeable symptoms, while others face seizures, intellectual disability, and organ damage that require lifelong management.
What Causes Tuberous Sclerosis
TSC is caused by a mutation in one of two genes: TSC1 or TSC2. The TSC1 gene produces a protein called hamartin, and the TSC2 gene produces a protein called tuberin. These two proteins bind together inside cells to form a complex that acts as a brake on cell growth. Specifically, the complex regulates a signaling pathway controlled by a protein called mTOR, which tells cells when to grow, divide, and make new proteins.
When either gene is mutated, the brake fails. mTOR stays permanently switched on, and cells grow larger and multiply when they shouldn’t. The result is clusters of abnormal, oversized cells that form benign growths (called hamartomas) throughout the body. A mutation in just one copy of either gene is enough to disrupt the complex and trigger this overactivation.
About one-third of TSC cases are inherited from a parent, while roughly two-thirds arise from new, spontaneous mutations. The condition follows an autosomal dominant pattern, meaning a child needs only one copy of the mutated gene to develop TSC. However, actual tumor formation typically requires a “second hit,” where the remaining healthy copy of the gene is also lost or damaged in a specific cell, allowing that cell line to grow unchecked.
How TSC Affects the Brain
Neurological problems are the most common and often the most serious aspect of TSC. Three types of brain lesions define the condition: cortical tubers (areas of abnormal tissue in the outer layer of the brain), subependymal nodules (small growths along the walls of the brain’s fluid-filled ventricles), and subependymal giant cell astrocytomas (SEGAs), which are slow-growing tumors that develop from those nodules. SEGAs can block the flow of cerebrospinal fluid and cause dangerous pressure buildup in the brain.
Seizures are extremely common, affecting the majority of people with TSC. They often begin in infancy, sometimes as infantile spasms, a particularly severe seizure type that involves sudden, brief jerking movements. As children grow, they may experience focal seizures (affecting one part of the brain) or tonic-clonic seizures (the full-body convulsions most people picture when they think of epilepsy). Early and aggressive seizure control matters because uncontrolled seizures in young children can worsen developmental outcomes.
Behavioral and Psychiatric Effects
TSC doesn’t stop at seizures. A wide range of behavioral, psychiatric, and learning difficulties fall under the umbrella term TAND (TSC-associated neuropsychiatric disorders). Autism spectrum disorder occurs in 25% to 50% of people with TSC, and ADHD affects 30% to 50%. Depression and anxiety disorders are also strikingly common, showing up in 30% to 60% of individuals. These conditions can appear at any age and sometimes cause more day-to-day difficulty than the physical symptoms, yet they’re frequently underdiagnosed because medical attention tends to focus on seizures and tumors.
Skin Signs and Early Detection
Skin changes are often the first visible clue that someone has TSC, and they appear in nearly all affected individuals. The earliest sign is usually ash-leaf spots: flat, off-white patches of skin, typically 1 to 3 centimeters across, found most often on the trunk and buttocks. These are present at birth or appear during infancy in more than 90% of people with TSC. One or two pale spots are common in the general population and don’t necessarily indicate TSC, but three or more are considered a major diagnostic sign.
Facial angiofibromas, small reddish bumps that cluster across the nose and cheeks, typically develop in early childhood and become more prominent with age. Other skin features include Shagreen patches (thickened, slightly raised areas of skin with a texture resembling an orange peel, usually on the lower back) and periungual fibromas (fleshy growths that emerge around or under the fingernails and toenails, more common in adolescence and adulthood). Because these skin findings can be spotted without any imaging or lab work, they play a key role in prompting further evaluation.
Kidney and Heart Involvement
About 80% of people with TSC develop kidney growths called angiomyolipomas, which are benign tumors made up of blood vessels, smooth muscle, and fat. Unlike the sporadic kidney tumors that occasionally occur in the general population, TSC-associated angiomyolipomas tend to be bilateral (in both kidneys), multifocal, and larger. They also grow faster and carry a greater risk of rupture and internal bleeding. Tumors that exceed 4 centimeters are considered particularly dangerous because they can cause life-threatening hemorrhage. Routine kidney monitoring is a standard part of TSC care throughout life.
Heart tumors called cardiac rhabdomyomas are another hallmark, and they often appear before birth. These growths are frequently detected on prenatal ultrasound and are sometimes the very first indication that a baby has TSC. Most are asymptomatic, but in some cases they can obstruct blood flow within the heart or trigger abnormal heart rhythms, causing symptoms like difficulty breathing and poor feeding in newborns. The reassuring part: cardiac rhabdomyomas tend to shrink on their own during infancy and early childhood, so surgery is rarely needed unless they’re causing significant problems.
How TSC Is Diagnosed
Diagnosis relies on a combination of clinical features and, when available, genetic testing. Clinicians use an internationally agreed-upon set of major and minor criteria. Major features include things like cortical tubers, facial angiofibromas, cardiac rhabdomyomas, kidney angiomyolipomas, and multiple ash-leaf spots. Minor features include less specific findings such as dental pits, skin tags, and certain bone lesions. A definite diagnosis requires either two major features or one major feature plus two minor features. Genetic testing that identifies a disease-causing mutation in TSC1 or TSC2 is independently sufficient for diagnosis, even without clinical signs.
In practice, the path to diagnosis varies wildly depending on when symptoms appear. Some children are identified prenatally through a heart tumor on ultrasound. Others aren’t diagnosed until adulthood, when mild skin findings or a kidney tumor discovered incidentally finally prompt a closer look.
Treatment and Management
Because the underlying problem in TSC is an overactive mTOR pathway, medications that inhibit mTOR have become a cornerstone of treatment. These drugs can shrink kidney angiomyolipomas, reduce the size of brain SEGAs, and in some cases improve seizure control. They don’t cure the condition, and tumors tend to regrow if the medication is stopped, but they’ve significantly reduced the need for surgery in many patients.
Seizure management often requires a combination of anti-seizure medications, and some children with drug-resistant epilepsy benefit from surgical options such as removing a specific cortical tuber that’s acting as a seizure focus. For the neuropsychiatric side of TSC, treatment follows the same principles used in the general population: behavioral therapy, educational support, and medication for conditions like ADHD, anxiety, or depression as needed. Regular screening for TAND symptoms is now recommended at every clinical visit because these issues evolve over time.
Lifelong surveillance is the reality for most people with TSC. That typically means periodic brain imaging to watch for SEGA growth, kidney imaging to monitor angiomyolipomas, skin exams, lung screening (particularly for women, who face a risk of a lung condition called LAM), and ongoing assessment of learning and mental health. The frequency and type of monitoring shift with age, but the need for it doesn’t go away.